MICROBOT MEDICAL INC. - COMMON STOCK

Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System

04 3 2025 08:30:00 提供 Nasdaq GlobeNewswire

Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting

25 2 2025 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Closes $13 Million Registered Direct Offering

11 2 2025 18:15:48 提供 Nasdaq GlobeNewswire

Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

10 2 2025 08:00:00 提供 Nasdaq GlobeNewswire

Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting

04 2 2025 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®

21 1 2025 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors

13 1 2025 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Closes $8.6 Million Registered Direct Offering

10 1 2025 10:25:51 提供 Nasdaq GlobeNewswire

Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

08 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility

07 1 2025 16:15:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

06 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®

30 12 2024 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access

10 12 2024 10:18:37 提供 Nasdaq GlobeNewswire

Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System

10 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025

15 10 2024 08:38:00 提供 Nasdaq GlobeNewswire

Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up

30 9 2024 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

17 9 2024 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System

22 8 2024 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization

13 8 2024 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System

01 8 2024 08:30:00 提供 Nasdaq GlobeNewswire